Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. develops and commercializes medical technology for patients with cardiorenal conditions, including Aquadex SmartFlow ultrafiltration therapy for fluid removal in fluid overload. Company news commonly covers financial results, Aquadex software and product updates, patent activity for catheter technology, clinical case studies in pediatric and heart-failure care, medical-meeting participation, commercial territory expansion, and hospital-support initiatives.
Nuwellis (Nasdaq: NUWE) announced a priced-at-the-market private placement and warrant inducement expected to raise approximately $5.0 million in gross proceeds prior to fees. The transaction includes 994,537 shares (or pre-funded warrants) plus 1,989,074 private placement warrants at a combined price of $3.09.
The company agreed to a warrant inducement: certain existing warrants will be exercised to buy 623,585 shares at an amended exercise price of $3.09, and Nuwellis will issue 1,247,170 new warrants exercisable at $2.84 for five years after resale registration effectiveness. Closing is expected on or about January 30, 2026. Ladenburg Thalmann served as placement agent.
Nuwellis (Nasdaq: NUWE) entered a Securities Purchase Agreement to acquire Rendiatech Ltd. on Jan 29, 2026, expanding its cardiorenal portfolio into real-time kidney function monitoring. The move adds Rendiatech’s Clarity™ automated continuous urine-output monitoring to Nuwellis’ critical-care offerings and remains subject to customary closing conditions.
The company expects to leverage existing commercial infrastructure and clinical relationships to integrate the technology and pursue future urine-based analytics and broader kidney assessment capabilities.
Nuwellis (Nasdaq: NUWE) announced board changes effective January 21, 2026: Katharyn Field and Mika Grasso were appointed to the board, and Dave McDonald, Mike McCormick, and Dr. Maria Costanzo resigned.
The company said the resignations were not due to any disagreement with Nuwellis on operations, policies, or practices. Management thanked the departing directors and said the new directors bring financial, operational, and governance experience. Additional details are disclosed in the company’s SEC Form 8-K.
Nuwellis (Nasdaq: NUWE) announced that the U.S. Patent and Trademark Office issued a new U.S. patent tied to U.S. Patent Application No. 18/298,810 on January 6, 2026.
The patent covers advanced safety mechanisms for blood return line clamps in extracorporeal blood filtration systems, with specific relevance to pediatric extracorporeal therapy and the Vivian™ Pediatric CRRT System currently in development. Nuwellis said the invention aims to improve reliability and consistency of blood flow control, support stable system performance for small patient volumes, and strengthen the company’s pediatric intellectual property portfolio and cardio-renal strategy.
Nuwellis (Nasdaq: NUWE) announced real-world data from Lenox Hill Hospital presented at ASN Kidney Week 2025 showing Aquadex ultrafiltration used across critical-care indications including oliguric AKI, post-cardiac-surgery volume overload, and pre-operative ESRD optimization.
The retrospective review of 69 cases (2018–2024) reported an average 6.4 liters removed per patient over a mean 78 hours with stable hemodynamics, including patients on vasopressors, supporting broader clinical utility of precision ultrafiltration.
Nuwellis (Nasdaq: NUWE) announced that a leading children’s hospital in the Northeast U.S. has initiated an Aquadex Ultrafiltration Program on Dec. 4, 2025. Pediatric nephrology and cardiology teams are adopting Aquadex for its minimal extracorporeal volume and real-time hematocrit monitoring to manage fluid-sensitive, high-acuity pediatric patients.
The company says Aquadex usage is expanding across leading children’s hospitals nationwide and is being integrated into care pathways for complex cardiac, cardio-renal, and critical care cases, supporting Nuwellis’ pediatric growth strategy.
Nuwellis (Nasdaq: NUWE) reported third quarter 2025 results on Nov 12, 2025, delivering $2.2 million total revenue, down 6% year‑over‑year and up 29% sequentially.
The company reported a 65.2% gross margin, operating expenses of $4.1 million (up 30% YoY) and an operating loss of $2.7 million. Nuwellis ended the quarter with $3.1 million cash, no debt, and raised $1.9 million through an ATM.
Operational milestones include first Aquadex therapies delivered in hospital‑based outpatient settings under a new CMS code, U.S. launch of a 24‑hour circuit and dual‑lumen extended‑length catheter, accelerated pediatric development via an NIH‑funded collaboration and a newly issued U.S. patent, plus a manufacturing transition and international wind‑down to focus on U.S. growth.
Nuwellis (Nasdaq: NUWE) announced a notice of allowance from the U.S. Patent and Trademark Office dated Nov 10, 2025 for a patent covering advanced safety mechanisms for blood return line clamps used in extracorporeal blood filtration systems, including the Vivian Pediatric CRRT System in development.
The technology dynamically adjusts clamping force, reconditions tubing under defined thermal conditions, and adds thermal insulation to improve material stability. This patent supplements a Sept 2025 patent for hemolysis sensing and complements NIH grant-funded research and Aquadex pediatric use data to inform Vivian design.
Nuwellis (Nasdaq: NUWE) will release its third quarter 2025 financial results on November 12, 2025. The company will host a conference call and live webcast at 9:00 AM ET to discuss results and provide a general business update.
Investors can access the live webcast on the company's Investors page at https://ir.nuwellis.com or join the call by dialing 1-800-274-8461 (U.S.) or 1-203-518-9814 (international) using conference ID NUWEQ3. An audio archive will be posted on the Investors page after the call.
Nuwellis (Nasdaq: NUWE) announced groundbreaking results from their ULTRA-Peds registry study evaluating the Aquadex System in pediatric patients with kidney conditions. The multi-center study, involving 91 pediatric patients across 8 U.S. centers, demonstrated remarkable outcomes with a 92% survival rate during treatment and 66% survival to hospital discharge.
The study included patients with congenital heart disease (30%), end-stage renal disease (25%), and malignancy (14%). The Aquadex therapy showed strong procedural success, with 86% of circuits completing treatment without interruption. Building on these results, Nuwellis is developing Vivian, a dedicated pediatric CRRT system for infants weighing 2.5-20kg, supported by a $3 million NIH grant.